SIU Academy® - Official eLearning Portal of SIU (Société Internationale d'Urologie)

The Design and Initial Survival Analysis Outcomes from the STAMPEDE Trial - an eSeries supported by SIU’s corporate sponsor, Sanofi Oncology
SIU Academy®. James N. 12/15/15; 108697 Topic: Research
Prof. Nicholas James
Prof. Nicholas James
Login now to access Regular content available to all registered users.

To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.

You may also access SIU content "anytime, anywhere" with the FREE SIU ACADEMY App for iOS and Android.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:
- Explain the changing prognosis of men starting long-term ADT
- Define the role of radiotherapy in M0 disease
- Discuss the role of chemotherapy in hormone-naïve prostate cancer
- Understand the evolving data on use of zoledronic acid in prostate cancer
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies